ClinicalTrials.gg
RecruitingNCT07358780REASSERTUpdated Feb 13, 2026

Remibrutinib in Real-world Clinical Practice - a US Sub-study

An observational study in Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know · 2 judgments

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
505
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 38 studies in Chronic Urticaria by Novartis — 7 open to participants now, 12 under way, 5 of them phase 3. Chronic Urticaria · Novartis.

Planned enrollment
4th of 10
505 · median 484
Started
2026
with 6 others
Observational
10 of 38
5 open now
Primary completion
2029-09
later than 9 of 11 live
Registered
32nd of 38
by date

Among the 38 studies in Chronic Urticaria by Novartis, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 7 that started in 2026, is one of 10 observational ones, reaches primary completion later than 9 of the 11 other live ones, and was the 32nd registered.

Chronic Urticaria

199 studies on the registry are indexed under Chronic Urticaria; 51 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

7 of the 38 studies in Chronic Urticaria by Novartis are open now, in 9 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Chronic Urticaria by Novartis, or all of them as a file.
02

Study summary

Prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, a new treatment option, covering a broader, real-world clinical practice population.

Read the detailed description

This is a prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, covering a broader, real-world clinical practice population. This local US study is part of an umbrella design which brings the evidence needs from multiple countries under the REASSERT global program (CLOU064A2402).

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • Remibrutinib
  • Non-Interventional Study
  • Chronic Spontaneous Urticaria
  • Second-generation H1 antihistamine
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a confirmed diagnosis of primary CSU by the treating physician.
  • Aged at least 18 years on the date of enrolment.
  • Written of the patient to participate in the study (according to country specifications) and willingness to complete full follow-up period of 24 months.
  • Cohort-specific observational inclusion criteria:

    • Cohort 1: Inadequate control of CSU despite licensed dose of sgH1-AH (no other pre-treatments permitted) and decision (independent of study enrolment) to escalate sgH1-AH treatment.
    • Cohort 2: Inadequate control of CSU despite licensed dose or escalated sgH1-AH(s) (no other pre-treatment with exception of first generation H1-AH permitted) with decision (independent of study enrolment) to switch to remibrutinib treatment as per local label.
    • Cohort 3: Any other treatment received in addition to H1-AH, any time during patients' CSU treatment history, with decision (independent of study enrolment) to switch to remibrutinib treatment as per local label. Note, occasional rescue medication is out of scope for cohort definition. If a patient had been on continuous steroids for at least three weeks during treatment history, they will be included in cohort 3.

Note: Candidate patients must not have initiated the next escalated treatment step (i.e. up dosed AH for cohort 1, or remibrutinib for cohorts 2 and 3) prior to their enrolment to ensure the baseline visit captures their clinical status before treatment escalation.

Exclusion criteria

Exclusion Criteria:

  • Currently enrolled in a clinical trial or on any experimental treatment.
  • Patients within the safety follow-up phase of a previous interventional or non-interventional study.
  • Patients who received remibrutinib as an medical product during a remibrutinib interventional study or MAP/PSDS at any time in the past.
  • Patients not capable or willing to continuously provide ePRO/eDiary data via electronic means throughout the duration of the study.
  • Patients who are treated with remibrutinib outside of the local label.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
505 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Inadequate control of CSU despite licensed dose of sgH1-AH (no other pre-treatments permitted) and decision to escalate sgH1-AH treatment

  • Cohort 2

    Inadequate control of CSU despite licensed dose or escalated sgH1-AH(s) (no other pre-treatment with exception of first generation H1-AH permitted) with decision to switch to remibrutinib treatment as per local label

  • Cohort 3

    Any other treatment received in addition to H1-AH, any time during patients' CSU treatment history, with decision to switch to remibrutinib treatment as per local label

This study also gives RemibrutinibStudies of RemibrutinibRemibrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. UAS7 score

    Urticaria Activity Score over 7 days UAS7 is based on 2 daily questions scored 0-3 per day, ranging from 0 (complete control) to 42 (poor control)

    Time frame: 12 weeks after initiating remibrutinib treatment

Secondary outcomes

  1. UCT7 score

    Urticaria Control Test is looking retrospectively for 7 days (UCT7) and consists of 4 questions. Each question is scored 0-4, with a total score range of 0 (poor control) to 16 (well controlled).

    Time frame: 12 weeks after initiating remibrutinib treatment

  2. Number and proportion of participants with well-controlled disease and complete disease

    Proportion of patients with UCT score ≥12 and UAS7 score ≤6. Urticaria Control Test (UCT) consists of 4 questions scored 0 (very much) to 4 (not at all), with a total score range of 0 to 16. High scores indicates better disease control. Urticaria Activity Score over 7 days (UAS7) is based on 2 daily questions, with daily score of 0 to 6 and weekly score of 0 to 42. Lower scores suggests urticaria free and well controlled urticaria.

    Time frame: Up to 24 months

  3. Change from baseline (CFB) in UCT score

    Change in UCT score over time. Urticaria Control Test (UCT) consists of 4 questions scored 0 (very much) to 4 (not at all), with a total score range of 0 to 16. Highest scores indicates better disease control. The study is not powered to detect any specific difference and the purpose is to estimate any observed difference descriptively.

    Time frame: Up to 24 months

  4. Change from Baseline in UAS7 score ≥ minimal important difference

    Urticaria Activity Score over 7 days (UAS7) is based on 2 daily questions, with daily score of 0 to 6 and weekly score of 0 to 42. Lower scores suggests urticaria free and well controlled urticaria. The study is not powered to detect any specific difference and the purpose is to estimate any observed difference descriptively.

    Time frame: Up to 24 months

  5. Change in angioedema activity score (AAS7) from baseline

    Angioedema Activity Score (AAS7) is assessing disease activity over 7 days in patients with urticaria. The score is based on 5 daily questions scored 0 (no discomfort) to 3 (severe discomfort), with weekly score ranging from 0 to 15. Higher scores indicates greater severity of angioedema.

    Time frame: Up to 24 months

  6. Number of weeks without angioedema

    Number of weeks without angioedema evaluated using application entries.

    Time frame: Up to 24 months

  7. Number of participants with rescue medication requirement

    Number of participants with rescue medication requirement

    Time frame: Up to 24 months

  8. Characterize CSU relapse

    CSU relapse by frequency and presentation

    Time frame: Up to 24 months

  9. UCT score

    Urticaria Control Test (UCT) consists of 4 questions scored 0 (very much) to 4 (not at all), with a total score range of 0 to 16. High scores indicates better disease control. The study is not powered to detect any specific difference and the purpose is to estimate any observed difference descriptively.

    Time frame: Up to 24 months

  10. UAS7 score

    Urticaria Activity Score over 7 days (UAS7) is based on 2 daily questions, with daily score of 0 to 6 and weekly score of 0 to 42. Lower scores suggests urticaria free and well controlled urticaria. The study is not powered to detect any specific difference, descriptive analysis of difference over time will be presented.

    Time frame: Up to 24 months

  11. Number of participants with administration of remibrutinib as monotherapy

    Number of participants with remibrutinib as monotherapy in cohort 2 and 3

    Time frame: Up to 24 months

  12. Monotherapy duration

    Duration of remibrutinib as monotherapy expressed by days, weeks or months in cohort 2 and 3

    Time frame: Up to 24 months

  13. Number of participants with Administration of remibrutinib as monotherapy with "on demand" sgH1-AH

    Number of participants with Administration of remibrutinib as monotherapy with "on demand" sgH1-AH in cohort 2 and 3

    Time frame: Up to 24 months

  14. Duration of monotherapy with "on demand" sgH1-AH

    Duration of remibrutinib therapy with "on demand" sgH1-AH expressed by days, weeks or months in cohort 2 and 3

    Time frame: Up to 24 months

  15. Number of participants with usage of concomitant sgH1-AHs and additional prescribed CSU treatments

    Descriptive analysis of concomitant sgH1-AHs

    Time frame: Up to 24 months

  16. Number of participants with administration of CSU-related treatment(s) outside of local and/or international guidelines

    Number of participants with administration of CSU-related treatment(s) outside of local and/or international guidelines

    Time frame: Up to 24 months

  17. Demonstrate relationship between non-adherence to local/international guidelines and impact on patient, disease control, treatment patterns and HCRU during early and long-term follow-up

    Demonstrate relationship between non-adherence to local/international guidelines and impact on patient, disease control, treatment patterns and HCRU during early and long-term follow-up

    Time frame: Up to 24 months

  18. Delay of treatment escalation contrary to local and/or international guidelines when UCT <12 or UAS>6

    Delay of treatment escalation contrary within 2-4 weeks from up-dosed sgH1-AH when UCT \<12 or UAS\>6 at time points measuring UCT7 (early) / UCT (month 3 onwards) / UAS7 group. This will be measured by time in days/months without escalation, with UCT\<12 or UAS7\>6 at time points measuring UCT7 / UCT (month 3 onwards) / UAS7 group

    Time frame: Up to 24 months

  19. Time without escalation, with UCT<12 or UAS7>6

    Time in days/months without escalation while UCT score is below 12 OR UAS7 score above 6. Urticaria Control Test consists of 4 questions, score below 12 indicates poor disease control. Urticaria Activity Score over 7 days is based on 2 daily questions with a maximum daily score of 6 and weekly total score up to 42. Lower scores indicates better urticaria control.

    Time frame: Up to 24 months

  20. Number of participants with escalation to remibrutinib

    Number of patients with escalation to remibrutinib (cohort 1), time to escalate, prior medications/escalations, and disease control at time of escalation will be presented.

    Time frame: Up to 24 months

  21. Number of participants with administration of above the licensed dose of sgH1-AH prior to remibrutinib switch

    Number of participants receiving escalated doses of sgH1-AH above the licensed dose (2 times, 3 times, 4 times, \>4 times) prior to remibrutinib switch. This will be presented for cohort 1 and 2.

    Time frame: Up to 24 months

  22. Number of sgH1-AH treatment escalations and switches prior to remibrutinib escalation

    Number of sgH1-AH treatment escalations and switches prior to remibrutinib escalation

    Time frame: Up to 24 months

  23. Demonstrate benefit of early vs late treatment escalation to remibrutinib

    Demonstrate benefit of early vs late treatment escalation to remibrutinib

    Time frame: Up to 24 months

  24. Proportion of patients with uncontrolled angioedema escalated to remibrutinib

    Presence of angioedema will be reported through App and/or derived from AAS scores

    Time frame: Up to 24 months

  25. Proportion of patients requiring corticosteroids prior to switch to remibrutinib

    Proportion of patients requiring corticosteroids for disease control prior to switch to remibrutinib (cohort 1 and 2)

    Time frame: Up to 24 months

  26. Quality of life measured through DLQI score

    Dermatology Life Quality Index (DLQI) score consists of 10 questions scored from 0 (no impact at all) to 3 (very much). Total score ranges from 0 to 30, with lower scores showing lowest impact of disease on quality of life.

    Time frame: Up to 24 months

  27. Quality of life evaluated through Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) questionnaire scores

    Change over time in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) questionnaire. CU-Q2oL consists of 20 items rated from 0 (never) to 5 (very often). Total score ranges from 0 to 25, with lower scores showing better urticaria control. The study is not powered to detect any specific difference, descriptive analysis of difference over time will be presented.

    Time frame: Up to 24 months

  28. Quality of life measured through Sleep interference score

    Sleep interference will be evaluated though bespoke question. Maximum score along 7 days ranges from 0 to 21, lower scores showing lowest interference of CSU with sleep.

    Time frame: Up to week 12

  29. Quality of life measured through Hospital anxiety and depression scale (HADS)

    Quality of life will be evaluated through HADS measuring anxiety and depression components, as well as change from baseline in HADS score. Hospital Anxiety and Depression Score (HADS) is a 14 item questionnaire, 7 item rating anxiety and 7 depression. Responses are rated from 0 (never) to 3 (almost all time) at each question. Total score for anxiety and total score for depression range from 0 to 21, higher scores showing higher anxious/depressive symptomatology. Descriptive analysis will be presented.

    Time frame: Up to 24 months

  30. Number of events related to CSU or Health Care Resource utilisation

    Health Care resource utilisation (HCRU) will be evaluated based on quarterly and annualized number of health care resource utilisation related to CSU.

    Time frame: Up to 24 months

  31. Work productivity and activity impairment (WPAI-CU) score

    Work productivity assessed through WPAI questionnaire which consists of 6 questions, used to calculate 4 types of scores, absenteeism (work time missed), presenteeism (impairment at work/reduced on the job effectiveness), work productivity loss (overall work impairment), and activity impairment. The scores are expressed in percentage with higher numbers indicating greater impairment and less productivity at work.

    Time frame: Up to 24 months

  32. Incidence of AEs

    Incidence of AEs, including serious AEs in patients who initiated remibrutinib and in patients with sgH1-AH treatment alone

    Time frame: Up to 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Sep 2029, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Jan 22, 2026
StartActual
Feb 2, 2026
Primary completionEst.
Sep 30, 2029
CompletionEst.
Sep 30, 2029
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07358780
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Feb 2, 2026
Primary completion
Sep 30, 2029 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Feb 13, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion